

RESOLUTION

Subject: HPV Vaccination until age 45

Submitted by: Monalisa Tailor, MD

Referred to: Reference Committee

---

WHEREAS, human papillomavirus (HPV) is a common sexually transmitted infection associated with multiple cancers, including cervical, oropharyngeal, anal, penile, vulvar, and vaginal cancers; and

WHEREAS, HPV vaccination is a safe and effective preventive measure that significantly reduces the incidence of HPV-related infections, precancerous lesions, and cancers; and

WHEREAS, the U.S. Food and Drug Administration has approved HPV vaccination for individuals up to age 45; and

WHEREAS, the Advisory Committee on Immunization Practices (ACIP) recommends shared clinical decision-making regarding HPV vaccination for adults aged 27 through 45 who are not adequately vaccinated; and

WHEREAS, many adults aged 27–45 remain unvaccinated and may still be at risk for new HPV infections, particularly with new sexual partners or other risk factors; and

WHEREAS, expanding awareness and support for HPV vaccination in this age group may help reduce the burden of HPV-related cancers and improve public health outcomes; now, therefore, be it

RESOLVED, that KMA supports human papillomavirus (HPV) vaccination for eligible adults up to age 45; and be it further

RESOLVED, that KMA encourages physicians to engage in informed discussions with patients regarding the risks and benefits of HPV vaccination; and be it further

RESOLVED, that KMA supports efforts to improve access to HPV vaccination for adults up to age 45, including insurance coverage and public health initiatives; and be it further

RESOLVED, that KMA promotes education and awareness campaigns to increase understanding of HPV-related cancer prevention across all eligible age groups.